Diphenylpyraline

CHEMBL1492 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
281.4 g/mol
LogP
3.9
Phase
4

An antihistamine used to relieve allergy symptoms such as runny nose, sneezing, and itching. It works by blocking histamine receptors that mediate allergic responses.

Молекулярная масса

281,4000 g/mol

LogP

3,90

TPSA

12,50 Ų

Правило пяти Липинского

Соответствует

Механизм действия

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1CCC(OC(c2ccccc2)c2ccccc2)CC1

InChI

InChI=1S/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3

Molecular Formula

C19H23NO

HBD / HBA

- / 2

Вращаемые Связи

4

Тяжёлые Атомы

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

An antihistamine used to relieve allergy symptoms such as runny nose, sneezing, and itching. It works by blocking histamine receptors that mediate allergic responses.

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Yes, Diphenylpyraline is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1492. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3103. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.